Sfoglia per Relatore
Mostrati risultati da 1 a 4 di 4
Assessment of Minimal Residual Disease (MRD) in newly diagnosed Multiple Myeloma Patients enrolled in a Clinical Trial: Comparison of Next Generation Flow Cytometry (NGF) and Next Generation Sequencing (NGS).
2023/2024 NASOUTI AGHJEHROUD, HOSSEIN
Confronto tra next generation flow (NGF) e citometria a flusso a singola piattaforma (Single-Platform FC) per la valutazione di plasmacellule circolanti in pazienti affetti da mieloma multiplo di nuova diagnosi arruolati nello studio multicentrico italiano di fase IV REAL MM
2023/2024 BRUNO, FRANCESCA
Minimal Residual Disease (MRD) by Multiparametric Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) in Newly Diagnosed Multiple Myeloma patients: concordance analysis and impact on the outcome of transplant-eligible patients enrolled in the FORTE clinical trial.
2020/2021 MOSCUZZA, ROBERTA
The emerging role of Circulating Tumor Cells (CTCs) in Multiple Myeloma
2022/2023 PAGLIARA, GIADA
Mostrati risultati da 1 a 4 di 4
Legenda icone
- file disponibili solo agli amministratori
- nessun file disponibile